Theragnostic particles

Patent metadata

Field	Value
Publication number	US-9765122-B2
Application number	US-201414652645-A
Country	US
Kind code	B2
Filing date	Jan 20, 2014
Priority date	Jan 18, 2013
Publication date	Sep 19, 2017
Grant date	Sep 19, 2017

Abstract

The present invention provides viral-based nanoparticles for therapeutic and diagnostic use, and methods for making and using the nanoparticles. Specifically, such nanoparticles comprise decoration-competent viral particles shells such as expanded capsids of phages, stabilized with engineered decoration proteins that have been linked to one or more compounds not naturally occurring on a wild type viral capsid.

First claim

We claim:

1. A theragnostic particle, comprising a plurality of engineered decoration proteins bound to an outer surface of decoration competent viral particle shell, wherein the engineered decoration proteins comprise gpDS42C (SEQ ID NO: 10)linked to one or more compounds not naturally occurring on a wild type viral capsid, and wherein the one or more compounds have at least one feature selected from the group consisting of:
(a) the one or more compounds are non-proteinaceous compounds;
(b) the one or more compounds are present on the theragnostic particle in a defined ratio relative to the engineered decoration protein;
(c) the one or more compounds comprise two or more different compounds, wherein the two or more different compounds are present on the theragnostic particle in a defined ratio relative to each other; and
(d) the one or more compounds are linked to the engineered decoration protein at a site on the engineered decoration protein other than the N-terminus or the C-terminus, wherein the decoration competent viral particle shell comprises a bacteriophage lambda viral particle shell.

2. The theragnostic particle of claim 1 , wherein the one or more compounds are non-proteinaceous compounds.

3. The theragnostic particle of claim 1 wherein the one or more compounds are present on the theragnostic particle in a defined ratio relative to the engineered decoration protein.

4. The theragnostic particle of claim 1 , wherein the one or more compounds comprise two or more different compounds, wherein the two or more different compounds are present on the theragnostic particle in a defined ratio relative to each other.

5. The theragnostic particle of claim 1 , wherein the one or more compounds are linked to the engineered decoration protein at a site on the engineered decoration protein other than the N-terminus or the C-terminus.

6. The theragnostic particle of claim 1 , wherein the engineered decoration proteins comprise engineered decoration proteins linked to one or more compounds that have at least one feature selected from the group consisting of (b), (c), and(d) according to claim 1 , wherein the compounds are selected from the group consisting of nucleic acids, lipids, carbohydrates, polypeptides, polymers, organic molecules, inorganic molecules, and combinations thereof.

7. The theragnostic particle of claim 1 , wherein the engineered decoration proteins comprise engineered decoration proteins linked to one or more non-proteinaceous compounds selected from the group consisting of nucleic acids, lipids, carbohydrates, polymers, organic molecules, inorganic, and combinations thereof.

8. The theragnostic particle of claim 1 , wherein the one or more compounds have at least one feature selected from the group consisting of (b),(c), and (d) according to claim 1 , and wherein the compounds are selected from the group consisting of therapeutic compounds, diagnostic compounds, adjuvants, antigens, antibodies, and combinations thereof.

9. The theragnostic particle of claim 1 , wherein the one or more compounds linked to the decoration proteins comprise two or more different compounds.

10. The theragnostic particle of claim 1 , wherein the bacteriophage lambda particle shell is an expanded bacteriophage lambda particle shell.

11. A pharmaceutical composition, comprising:
(a) the theragnostic particle of claim 1 ; and
(b) a pharmaceutically acceptable carrier.

12. An isolated recombinant protein comprising the amino acid sequence of SEQ ID NO: 10 (gpD(S42C)).

13. The isolated recombinant protein of claim 12 , further comprising one or more compounds linked to the recombinant protein via the cysteine at position 42.

14. An isolated nucleic acid encoding the recombinant protein of claim 12 .

15. A recombinant expression vector comprising the isolated nucleic acid of claim 14 .

16. The theragnostic particle of claim 1 , wherein the one or more compounds comprise mannose.

17. The theragnostic particle of claim 1 , wherein the one or more compounds are non-proteinaceous compounds, and wherein the one or more compounds are selected from the group consisting of therapeutic compounds, diagnostic compounds, adjuvants, and combinations thereof.

Assignees

• Univ Washington Through Its Center For Commercialization

Inventors

• Catalano Carlos Enrique
• Chang Jenny Ren-Jye

Classifications

• C12N2795/10042

  virus or viral particle as vehicle, e.g. encapsulating small organic molecule · CPC title

• C07K14/005 Primary

  from viruses · CPC title

• C12N7/00 Primary

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• C12N2795/10023

  Virus like particles [VLP] · CPC title

• A61K38/177

  Receptors; Cell surface antigens; Cell surface determinants · CPC title